Recent developments highlight Ocugen's progress in expanding its gene therapy pipeline, securing regulatory pathways, and advancing clinical trials, alongside financial updates and risk management disclosures.

• Ocugen expanded the reach of its OCU400 gene therapy through a $255 million milestone licensing deal with Roots Pharmaceutical for the MENA region [N1][N2].
• The company gained an approval pathway in the Bahamas for OCU400 targeting retinitis pigmentosa [N3].
• Ocugen is advancing three gene therapy BLA filings as its retinal pipeline progresses, including OCU410 in Phase III for geographic atrophy [N4].
• The FDA granted RMAT designation to OCU410 for dry AMD-related geographic atrophy [N8].
• Ocugen reported a net loss of $3.6 million and basic and diluted EPS of -$0.01 for Q3 2026, with cash and cash equivalents of $24.6 million as of September 30, 2026 [S2].
• The company maintains a cybersecurity risk management program overseen by senior IT management and the Board, with regular reporting and risk mitigation strategies [S1].
• Research and development expenses have increased, reflecting ongoing clinical development activities [N5][N6].

Ocugen's advancement of multiple gene therapy candidates into late-stage clinical trials and regulatory pathways, combined with strategic licensing deals expanding geographic reach, demonstrate operational progress. The company's focused pipeline on retinal diseases addresses significant unmet needs, and regulatory designations like RMAT may facilitate accelerated development and review processes. Continued R&D investment supports pipeline maturation.

Ocugen operates in a high-risk biotech environment with ongoing net losses and liquidity ratios below 1, indicating potential funding challenges. Clinical and regulatory risks inherent to gene therapy development remain significant. The company's reliance on milestone-based licensing deals and the need for successful BLA filings introduce execution risks. Cybersecurity incidents could disrupt operations despite active risk management.

Ocugen's moat is based on its specialized gene therapy platform targeting retinal diseases, a niche with high unmet medical need. The company's regulatory designations, such as FDA RMAT, and its expanding geographic licensing agreements provide barriers to entry. Its late-stage clinical pipeline and proprietary technology contribute to potential competitive advantages in the gene therapy space for ophthalmic conditions.

• Clinical and Regulatory Risk: Gene therapy development involves significant clinical trial and regulatory approval risks that could delay or prevent product commercialization.
• Financial and Liquidity Risk: Current ratio below 1 and net losses indicate potential liquidity constraints requiring additional financing.
• Execution Risk: Dependence on successful milestone achievements and licensing agreements to expand market reach and fund operations.
• Cybersecurity Risk: Potential cybersecurity incidents could materially disrupt product development and business operations despite active risk management.

• Ocugen, Inc. is a biotechnology company focused on gene therapies, particularly for retinal diseases such as retinitis pigmentosa and geographic atrophy.
• The company has a gene therapy product candidate named OCU400 targeting retinal diseases, including retinitis pigmentosa.
• Ocugen has expanded the reach of OCU400 through a licensing deal with Roots Pharmaceutical for the MENA region, involving a $255 million milestone agreement.
• The company has gained an approval pathway in the Bahamas for OCU400 for retinitis pigmentosa.
• Ocugen is advancing multiple gene therapy programs, including OCU410, which is in Phase III clinical trials for geographic atrophy related to dry age-related macular degeneration (AMD).
• The company targets three biologics license application (BLA) filings for its retinal gene therapy pipeline.
• Ocugen received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for OCU410 in dry AMD-related geographic atrophy.
• Financially, as of September 30, 2026, Ocugen reported cash and cash equivalents of $24.6 million and current assets of $91.4 million, with current liabilities of $118.9 million, resulting in a current ratio of 0.77 and a cash ratio of 0.21.
• The company reported a net loss of $3.6 million and basic and diluted earnings per share of -$0.01 for the quarter ended September 30, 2026.
• Ocugen's cybersecurity risk management program is overseen by an experienced Associate Vice President of IT & Facilities, with regular reporting to the Board and Audit Committee.
• The Board of Directors actively oversees risk management including cybersecurity risks, with quarterly briefings from management.
• Recent quarterly earnings calls and reports provide detailed operational and financial updates.
• The company completed a $22.5 million offering of common stock in January 2026.
• Ocugen's research and development expenses have risen, reflecting ongoing clinical and development activities.